These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 19025217

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine.
    Kress HG.
    Eur J Pain; 2009 Mar; 13(3):219-30. PubMed ID: 18567516
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
    Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C.
    J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
    [Abstract] [Full Text] [Related]

  • 27. Buprenorphine TDS: use in daily practice, benefits for patients.
    Radbruch L.
    Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
    Poulain P, Denier W, Douma J, Hoerauf K, Samija M, Sopata M, Wolfram G.
    J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
    [Abstract] [Full Text] [Related]

  • 30. [Buprenorphine matrix patch well tolerated. The challenge of tumor pain].
    MMW Fortschr Med; 2006 Jan 12; 148(1-2):42-3. PubMed ID: 16612846
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
    Apolone G, Corli O, Negri E, Mangano S, Montanari M, Greco MT, Cancer Pain Outcome Research Study Group (CPOR SG) Investigators, Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M, Nicora Maria F, Torri V, Zucco F.
    Clin J Pain; 2009 Oct 12; 25(8):671-82. PubMed ID: 19920716
    [Abstract] [Full Text] [Related]

  • 33. Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine.
    Aurilio C, Pace MC, Passavanti MB, Paladini A, Maisto M, Iannotti M, Pota V, D'amora E, Sansone P, Barbarisi M.
    Pain Pract; 2009 Oct 12; 9(2):105-14. PubMed ID: 19019049
    [Abstract] [Full Text] [Related]

  • 34. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
    Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, Standop J, Kloecker N, Nadstawek J.
    Eur J Pain; 2009 Aug 12; 13(7):737-43. PubMed ID: 18977159
    [Abstract] [Full Text] [Related]

  • 35. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S, Porzio G, Ferrera P, Fulfaro F, Aielli F, Verna L, Villari P, Ficorella C, Gebbia V, Riina S, Casuccio A, Mangione S.
    Eur J Pain; 2008 Nov 12; 12(8):1040-6. PubMed ID: 18353696
    [Abstract] [Full Text] [Related]

  • 36. A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.
    Schmid-Grendelmeier P, Pokorny R, Gasser UE, Richarz U.
    Curr Med Res Opin; 2006 Mar 12; 22(3):501-9. PubMed ID: 16574034
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Allergic contact dermatitis from transdermal buprenorphine.
    Vander Hulst K, Parera Amer E, Jacobs C, Dewulf V, Baeck M, Pujol Vallverdú RM, Giménez-Arnau A, Tennstedt D, Goossens A.
    Contact Dermatitis; 2008 Dec 12; 59(6):366-9. PubMed ID: 19076888
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Transdermal fentanyl in cancer patients with moderate-to-severe pain: a prospective examination.
    Iconomou G, Viha A, Vagenakis AG, Kalofonos HP.
    Anticancer Res; 2000 Dec 12; 20(6C):4821-4. PubMed ID: 11205226
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.